Patients with recurrent glioblastoma may derive a greater benefit from sacituzumab govitecan if they have high TROP2 expression.

The median overall survival was 10.15 months in patients who received epacadostat and 11.11 months in those who did not. Treatment with retifanlimab, bevacizumab, and hypofractionated radiotherapy ...

Pre-operative fractionated stereotactic radiotherapy (FSRT) may produce better outcomes than post-operative FSRT in cancer patients with brain metastases.

The combination of ACT001 and radiotherapy elicited responses and was considered well tolerated in a phase 2 trial of pediatric patients with newly diagnosed DIPG.

The US Food and Drug Administration (FDA) has granted accelerated approval to Ziihera (zanidatamab-hrii) for the treatment of adults with previously treated, unresectable or metastatic HER2-positive ...

More research is needed to investigate the cause of the decline in cutaneous melanoma incidence among young patients, researchers say.

(HealthDay News) — President-elect Donald Trump says he will nominate Mehmet Oz, MD, to head the Centers for Medicare & Medicaid Services. In a statement, Trump said that Oz will “work closely with ...

Hospitals around the country are conserving critical intravenous fluid supplies to cope with a shortage that may last months.

Source: Getty Images “Metformin may improve lung cancer-specific clinical outcomes in obese and overweight lung cancer patients and enhance immunotherapy efficacy in this growing population as well,” ...

Source: Getty Images Suboptimal rates of dMMR testing and immunotherapy use suggest “a need for ongoing clinician and patient education, given the survival benefit of immunotherapy in recurrent ...

In its accelerated approval decisions of new cancer drugs, the FDA might be underestimating the willingness of some patients ...

A CXB boost continues to provide an organ preservation benefit at 5 years, though there is some local regrowth after 3 years, ...